Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES.

Michael SzarekEsther ReijndersPh Gabriel StegJ Wouter JukemaMarkus SchwertfegerDeepak L BhattVera A BittnerRafael DiazSergio FazioGenevieve GaronShaun G GoodmanRobert A HarringtonHarvey D WhiteAndreas M ZeiherChrista CobbaertGregory G Schwartz

Published in: European journal of preventive cardiology (2024)

Keyphrases

cardiovascular events
coronary artery disease
cardiovascular disease
low density lipoprotein
metabolic syndrome
skeletal muscle